CD86/B7-2
Alpha Lifetech can provide CD86/B7-2 corresponding products, help each customer's research and development.
01
Introduction To CD86/B7-2
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. The introduction of CD86/b7-2 protein is a common target in medicine.
CD86 is a glycosylated protein consisting of 329 amino acids with a molecular weight of 70 kDa. It contains a single-pass transmembrane domain and a cytoplasmic domain, as well as an extracellular region, the latter containing an immunoglobulin superfamily V-like region and a C-like region as does CD80. CD86 is mainly expressed by antigen-presenting cells (APC), including dendritic cells (DC), Langerhans cells, activated macrophages, and B cells. Moreover, it is also constitutively expressed on the surface of syndactyly dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, germinal center B cells, and macrophages.
Function of Target CD86/B7-2
CD86 binds to the receptor CD28 protein on the surface of T cells to give signals to initial T cell activation, produce stimulatory effects: promote T cell activation, proliferation, and differentiation; induce the regulation of IL-2 receptors on the surface of T cells, increase the transcription of IL-2 mRNA, and promote the secretion of cytokines. Meanwhile, CD28 regulates the Fas / FasL-mediated cell apoptosis pathway, etc. During the immune response, the CD86 molecules on the APC can provide a costimulatory signal for T cell activation. CD86 interacts with the inducer CD28 and the inhibitor CTLA 4 and is the main synergistic factor in inducing T lymphocyte proliferation and IL-2 production. CD86 is also involved in regulating B cell function. By cross-linking to Ig receptors or in the presence of multiple cytokines, CD86 on the B cell surface is activated and expression is rapidly upregulated. In the humoral immune response, CD86 indirectly participates in humoral immunity by stimulating the CD4 + Th 2-type cells. Moreover, some studies have shown that CD86 can directly regulate the secretion of IgG in B cells and has important roles in B cell immune response.
Gene Pathway of Target CD86/B7-2
When CD86 binds to its receptors CD28 or CTLA-4, it triggers a cascade of signaling processes. These signals are transmitted through intracellular signaling molecules and ultimately affect the activation status and function of T cells. CD86 acts in concert with CD80 to provide the necessary costimulatory signals to T cells. This synergistic effect is essential for T-cell activation and proliferation. As an important molecule in the immune system, CD86 interacts with other immune molecules and cells, and together constitute a complex immunomodulatory network. This network ensures the precision and moderation of the immune response through fine regulatory mechanisms.
Fig 1: CD86 Gene Pathway. (Reference source: Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood. 2013 Jan 31;121(5):734-44.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD86/b7-2 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD86/b7-2 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD86/b7-2 protein products are also essential. Alpha Lifetech can provide CD86/b7-2 corresponding products and help each customer's research and development. Alpha Lifetech focuses on high-precision detection development and validation services to support drug screening and biosimilar discovery. Our detection methods, including ELISA, cell-based functional testing, and flow cytometry, have undergone rigorous sensitivity, specificity, and reproducibility testing. In addition to testing and development, our team also provides data analysis, scheme optimization, and cross-species reactivity testing to ensure reliable results.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64627 | 50ug,100ug,500ug | |
| ALP64607 | ALP64607-Recombinant Mouse CD86/B7-2 Protein, Fc Tag | 50ug,100ug,500ug |
| ALP64568 | 50ug,100ug,500ug | |
| ALP64567 | 50ug,100ug,500ug | |
| ALP64566 | 50ug,100ug,500ug | |
| ALP64565 | 50ug,100ug,500ug | |
Reference
[1] Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol. 2003 Jun;24(6):314-9.
[2] Darvish Z, Kheder RK, Faraj TA, Najmaldin SK, Mollazadeh S, Nosratabadi R, Esmaeili SA. A better understanding of the role of the CTLA-CD80/86 axis in the treatment of autoimmune diseases. Cell Biochem Funct. 2024 Jan;42(1):e3895.
[3] Lozanoska-Ochser B, Klein NJ, Huang GC, Alvarez RA, Peakman M. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J Immunol. 2008 Nov 1;181(9):6109-16.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102